|
Targeted, Enhanced Modification Of Lipid NanoparticlesTto Improve Tumor Therapeutic Efficacy
A method to inhibit small extracellular vesicles (sEVs) released by tumor cells to enhance lipid nanoparticle (LNP) accumulation in tumors.
Problem:
Lipid nanoparticles (LNPs) have shown promise as drug delivery systems for various diseases with several clinically approved products. However, their ability to deliver genes specifically to tumor cells...
Published: 4/11/2025
|
Inventor(s): Michael Mitchell, Ningqiang Gong, Wenqun Zhong, Wei Guo
Keywords(s): Bioengineering, Drug Delivery, Immunoncology, Oncology
Category(s): Technology Classifications > Therapeutics
|
|
Small molecules that target RNA structures within the CoV genome
Chemical structure of the three lead molecules derived from the focused library screen against OC43-infected Vero E6 cell screening (Zafferani et al 2021)
Invention Summary:
The SARS-CoV-2 pandemic, and the likelihood of future coronavirus pandemics, emphasized the urgent need for development of novel antivirals. Small-molecule chemical probes...
Published: 4/9/2025
|
Inventor(s): Amanda Hargrove, Blanton Tolbert, Gary Brewer, Neeraj Patwardhan, Mei-Ling Li
Keywords(s): Antiviral, Respiratory Disease
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Anti-sense Oligonucleotide Targets Insulin Receptor Isoform A
IR-A ASO targets the exon 10-12 junction in of IR-A mRNA.
Invention Summary:
Breast cancer is one of the most common cancers among women, and while effective treatment options exist, there remains a critical need to enhance their efficacy and reduce their off-target effects to minimize toxicity. Expression of Insulin receptor-A (IR-A),...
Published: 4/8/2025
|
Inventor(s): Teresa Wood, Christopher Galifi
Keywords(s):
Category(s): Technology Classifications > Cancer, Technology Classifications > Therapeutics
|
|
Tricyclic Inhibitors of Ribosome‐Inhibiting Proteins
An image that shows p-stalk binding blockage would lead to the prevention of damage caused by Shiga or Ricin toxins
Invention Summary:
Shiga Toxin-producing E. coli (STEC) are very common bacteria that can cause infections that lead to approximately 100,000 illnesses, 3,000 hospitalizations, and about 90 deaths annually in the United States....
Published: 3/31/2025
|
Inventor(s): Jacques Roberge, Xiao-Ping Li, Anastasiia Tsymbal, Nilgun Tumer
Keywords(s):
Category(s): Technology Classifications > Physical Sciences & Engineering, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Intranasally-Delivered Therapy For The Treatment Of Depression And Dementia
Intranasal nasal dantrolene nanoparticles alone, or in combination with lithium, can provide protection against depression and dementia with minimal or no side effects.
Problem:
Major depression disorder (MDD) affects 350 million patients in the world and about 16% of the population in USA. In addition, up to 50% of Alzheimer’s disease (AD)...
Published: 3/12/2025
|
Inventor(s): Huafeng Wei
Keywords(s): Aging, Immunology, Immunoncology, Infectious Disease, Inflammation, Neurodegenerative Diseases
Category(s): Technology Classifications > Therapeutics
|
|
Intranasal Dantrolene Nanoparticle Use For Treatment Of Alzheimer's Disease
Intranasal delivering of dantrolene nanoparticles could potentially be used to inhibit memory loss and reduce amyloid plaques in patients with Alzheimer's disease.
Problem:
Alzheimer’s disease (AD) is a devastating neurodegenerative disease. The deficit in the development of new drugs targeting the amyloid pathology over the past several...
Published: 3/12/2025
|
Inventor(s): Huafeng Wei, Qing Cheng Meng, Ge Liang, Maryellen Eckenhoff
Keywords(s): Aging, COVID-19, Nanotechnology, Neurodegenerative Diseases
Category(s): Technology Classifications > Animal Health, Technology Classifications > Chemical Processes and Synthesis, Technology Classifications > Food Science and Nutrition, Technology Classifications > Research Tools & Reagents, Technology Classifications > Therapeutics
|
|
Biocompatible And Low-Toxicity Lipid Nanoparticles (LNPs) For Selectively Delivering mRNA To The Bone Microenvironment
Ionizable LNPs with a rigid backbone of piperazine (PIP) linked to bisphosphonates (BPs) for the targeted delivery of mRNA to the bone.
Problem:
Available treatments for bone tissue related diseases provide only symptomatic relief and are associated with clinical challenges and potential side effects. Challenges persist in the delivery of therapeutic...
Published: 3/7/2025
|
Inventor(s): Michael Mitchell, Kyle Vining, Lulu Xue, Il-Chul Yoon
Keywords(s): Aging, Bioengineering, Drug Delivery, Gene Therapy, Orthopedics, Platform Technology, Women's Health
Category(s): Technology Classifications > Chemical Processes and Synthesis, Technology Classifications > Therapeutics
|
|
A Novel Selective HDAC11 Inhibitor with Broad Anti-Cancer Efficacy
HDAC11 is a Histone Deacetylase (HDAC) enzyme. However, HDAC11 has a high defatty-acylase activity while its deacetylation activity is virtually nonexistent, which is linked to poor prognosis in multiple cancers. This suggests that inhibition of HDAC11 can be used to treat cancers by modulating protein function. No potent and selective inhibitors for...
Published: 3/13/2025
|
Inventor(s): Edward Seto, Hening Lin
Keywords(s):
Category(s): Technology Classifications > Therapeutics
|
|
Anticancer IgG Against Multiple Epitopes on Live Tumors Upon Disruption of ‘Self’ Signaling by CD47
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis.
Problem:
Phagocytosis of ‘self’ cells is generally inhibited by a key macrophage checkpoint interaction between SIRPα on the macrophage and...
Published: 2/27/2025
|
Inventor(s): Dennis Discher, Jason Andrechak, Lawrence Dooling
Keywords(s): Antibody, Bioengineering, Cell Therapy, Drug Target, Immunology, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s): Technology Classifications > Therapeutics
|
|
BLTP3A (also known as UHRF1BP1) silenced CAR-T cells demonstrate elevated efficacy against High-grade serous carcinoma (HGSC)
Impairing BLTP3A elevates T cells activity via enhanced recycling of TCR and CAR machinery through the endosomal system.
Invention Summary:
Despite recent advances in cancer immunotherapy, objective responses remain rare. This is partly due to an incomplete understanding of the complex immunosuppressive mechanisms operating within the...
Published: 2/21/2025
|
Inventor(s): Kyle Payne, Fnu Kumari
Keywords(s):
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics, Technology Classifications > Cell Therapy
|